Cited 0 times in
Cited 0 times in
The avalglucosidase alfa phase 3 COMET trial in late-onset Pompe disease patients: Efficacy and safety results after 97 weeks
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.